Form 4: Amylyx Legal Officer Sells Shares for Tax Obligations

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold 3,419 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported a sale of common stock.
• The transaction involved the disposition of 3,419 shares of common stock.
• The shares were sold on February 23, 2026, at a weighted average price of $14.1422 per share.
• The sales were non-discretionary and executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Ms. Mazzariello beneficially owns 141,274 shares of Amylyx Pharmaceuticals common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it reduces insider ownership, the non-discretionary nature for tax purposes means it does not signal a change in management's confidence or outlook.

Positives

• The sale was non-discretionary, indicating it was not a voluntary decision to reduce exposure to the company's stock but rather a mandatory tax event.
• The transaction was made pursuant to a Rule 10b5-1 plan, which suggests a pre-arranged trading plan designed to comply with insider trading laws.

Negatives

• A reduction in direct insider ownership, even if for tax purposes, slightly decreases management's direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that non-discretionary sales by executives to cover tax obligations upon the vesting of restricted stock units are a routine occurrence in publicly traded companies. These transactions are typically pre-scheduled under Rule 10b5-1 plans and are generally not indicative of management's sentiment towards the company's future prospects.

Comparison to Industry Standards

• Not applicable. This filing reports a standard insider transaction for tax purposes, which does not lend itself to direct comparison with industry-specific operational or financial benchmarks.

Related Party Transactions

• The transaction involves an officer of the company selling shares, which is an insider transaction.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-discretionary nature mitigates concerns about management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale by an executive to cover tax obligations related to restricted stock unit vesting. It does not reflect a change in the company's fundamentals or management's outlook, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Amylyx Pharmaceuticals, AMLX, Gina Mazzariello, Chief Legal Officer, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Corporate Governance